Recombinant factor VIIa treatment in patients with uncontrollable, life-threating haemorrhage, an algorithm-based approach;Rationel behandling af ukontrollable, livstruende blødninger med anvendelse af rekombinant faktor VIIa

Ugeskrift for Laeger

Volumn 167, Issue 25-31, 2005, Pages 2756-2759

  Stensballe, Jakob ^a   Lethagen, Stefan ^b   Lippert, Freddy ^b   Johansson, Pär ^b  

^a University of Copenhagen   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ALGORITHM; BLEEDING; BLOOD BANK; BLOOD TRANSFUSION; DENMARK; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; LETHALITY; PRACTICE GUIDELINE; SHORT SURVEY; STANDARDIZATION; UNIVERSITY HOSPITAL;

BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; COAGULANTS; FACTOR VIIA; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; SAFETY;

EID: 21444459221     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004;18:245-59.
2. Dutton RP, McCunn M, Hyder M et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-19.
3. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.
4. Lodge JP, Jonas S, Oussoultzoglou E et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005;102:269-75.
5. Planinsic RM, Testa G, Emre S et al. Safety and efficacy of single bolus dose of recombinant factor VIIA in patients undergoing orthotopic liver transplantation: a randomized mulit-center study. Hepatology 2002;36:660A.
6. The 6th World Congress on Trauma, Shock, Inflammation and Sepsis. Munich, Germany, 2004. http://www.trauma-shock-sepsis-congress-munich-2004.org/press. html/marts 2005.
7. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
8. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000;85:487-91.
9. Martinowitz U, Michaelson M. Guidelins for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVVIa Task Force. J Thromb Haemost 2005; DOI: 10.1111/j.1538-7836.2005.01203.x.http://www.journalth.com/showPage.php? template=Articolo&id=13491&masterPage=articleprepublications.html/ marts 2005.
10. Karolinska Sjukhuset. Rekombinant koagulationsfaktor VIIa och dess nuvarande status som hemostatiskt medel vid kirurgi. http://www.janusinfo.se/ imcms/servlet/GetDoc?meta_id=5557/marts 2005.
11. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-8.